Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to DehydraTECH-CBD FDA Evaluation Following Successful Dosing in Multi-Week HYPER-H21-4 Human Clinical Study
Lexaria just completed dosing for its HYPER H21-4 human clinical study that dosed 64 patients aged between 40 and 70 with measured elevated blood pressure, stage 1 and stage 2 hypertension HYPER-H21-4, Lexaria’s most ambitious hypertension clinical study yet, builds on the success of HYPER-H21-1 and HYPER-H21-2, both completed in 2021 It explores the use of the company’s patented DehydraTECH(TM) technology in the potential treatment of hypertension Lexaria is confident that the additional data sets collected over the course of the study will lead to supplementary applications for DehydraTECH while providing valuable additional insights into the long-term health benefits of…